Merck and Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world.

(RTTNews) - Merck & Co Inc. (MRK), Monday announced that Health Canada has approved KEYTRUDA in combination with cisplatin-based chemoradiotherapy for patients with FIGO 2014 Stage III-IVA ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Merck & Co., Inc. stands seventh on our list and recently boosted Keytruda’s production.

Merck joins Big Pharma cost-cutting crowd, revealing plan to save $3B annually by 2027 By Kevin Dunleavy Jul 29, 2025 8:15am Merck layoffs Keytruda Gardasil ...

Keytruda is a prescription drug used to treat certain types of cancer. Learn more about how to know whether Keytruda is working and more.

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe subtypes.

SC Keytruda recently aced a phase 3 clinical trial in which it proved noninferiority compared to the original, intravenous version of the medicine in treating patients with non-small cell lung ...

The multiyear effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer drug Keytruda.